| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 9.08▼ | 9.04▼ | 9.03▼ | 9.77▼ | N/A |
| MA10 | 9.08▼ | 9.03▼ | 9.13▼ | N/A | N/A |
| MA20 | 9.05▼ | 9.19▼ | 9.72▼ | N/A | N/A |
| MA50 | 9.04▼ | N/A | N/A | N/A | N/A |
| MA100 | 9.32▼ | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | 0.094▲ | N/A | N/A | N/A |
| RSI | 46.168▼ | 32.992▼ | 21.740▼ | N/A | N/A |
| STOCH | 75.355 | 57.551 | 21.542 | N/A | N/A |
| WILL %R | -47.619 | -56.667 | -84.016▼ | N/A | N/A |
| CCI | -60.291 | 33.653 | -55.742 | N/A | N/A |
| ▲ GAP | $JBIO Open Gap Up %2 | Set Alert |
|
Friday, May 02, 2025 04:20 AM
On Friday, TD Cowen initiated coverage on Jade Biosciences (NASDAQ:JBIO), assigning a Buy rating to the company’s stock, which currently trades at $10, within its 52-week range of $9.02 to $13.50. The ...
|
|
Thursday, May 01, 2025 11:17 PM
On Friday, TD Cowen initiated coverage on Jade Biosciences (NASDAQ:JBIO), assigning a Buy rating to the company’s stock, which currently trades at $10, within its 52-week range of $9.02 to $13.50.
|
|
Monday, April 28, 2025 03:14 PM
Biotech firm Jade Biosciences Inc. has completed its merger with Aerovate Therapeutics Inc. (Nasdaq:AVTE), in a move that will put the former on the Nasdaq. Jade’s Vancouver-based CEO, Tom Frohlich, ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/05/25 | 9.16 | 9.165 | 9.015 | 9.015 | 12,395 |
| 08/05/25 | 9.51 | 9.51 | 8.82 | 9.00 | 310,783 |
| 07/05/25 | 10.15 | 10.4088 | 9.25 | 9.26 | 212,219 |
| 06/05/25 | 11.40 | 11.58 | 10.12 | 10.09 | 424,276 |
| 05/05/25 | 12.51 | 13.00 | 11.422 | 11.50 | 564,300 |
|
|
||||
|
|
||||
|
|